Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model.

Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model.

Triple-negative breast cancer (TNBC) is a highly aggressive phenotype that is resistant to standard therapy. Thus, the development of alternative therapeutic strategies for TNBC is essential. The purpose of our in vitro study was to evaluate the impact of p53 gene silencing in conjunction with the a...

Full description

Bibliographic Details
Main Authors: Cornelia Braicu, Valentina Pileczki, Laura Pop, Roxana Cojocneanu Petric, Sergiu Chira, Eve Pointiere, Patriciu Achimas-Cadariu, Ioana Berindan-Neagoe
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0120936

Internet

https://doi.org/10.1371/journal.pone.0120936

Similar Items